Artificial Intelligence in Pulmonary Hypertension: Advancements, Opportunities, and Challenges
Journal of Clinical Medicine · 07.11.2026 · 15 (21) · 8707
DOI: 10.3390/jcm15218707 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Clinical Medicine, online erschienen am 07.11.2026. Verfasst von Xinyi Li und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Ultrasound Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, 1277 Jiefang Avenue, Wuhan …. Die Arbeit nennt 124 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
Pulmonary hypertension (PH) is a progressive cardiopulmonary disorder associated with high morbidity and mortality. Delayed diagnosis, heterogeneous disease phenotypes, and variable treatment responses remain major clinical challenges. Artificial intelligence (AI), including machine learning and deep learning, has emerged as a promising tool for improving PH management. AI-based models have demonstrated promising performance in screening, diagnosis, classification, risk stratification, and prognosis prediction using multimodal data such as electrocardiography, chest radiography, computed tomography, cardiac magnetic resonance imaging, echocardiography, and electronic health records. Furthermore, AI may support individualized risk assessment, treatment-response prediction, early identification of right ventricular deterioration, and longitudinal remote monitoring. Emerging technologies, including explainable AI, federated learning, large language models, and digital twins, may further advance precision medicine in PH. Despite these advances, data quality, interpretability, privacy, and clinical implementation of AI remain challenges. This review summarizes current applications, opportunities, and challenges of AI in PH and discusses future directions for AI-assisted precision healthcare.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Ultrasound Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, 1277 Jiefang Avenue, Wuhan 430022, China.
- Clinical Research Center for Medical Imaging in Hubei Province, Wuhan 430022, China.
- Hubei Province Key Laboratory of Molecular Imaging, Wuhan 430022, China.
- Key Laboratory of Biological Targeted Therapy, Huazhong University of Science and Technology, Ministry of Education, Wuhan 430022, China.
ORCID-Profile: Li Zhang, Mingxing Xie, Mengmeng Ji
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Li, X., Zhang, L., Zhang, L., Xie, Y., Xie, M., Ji, M., He, Q., Wu, Z., Qin, S., & Li, Y. (2026). Artificial Intelligence in Pulmonary Hypertension: Advancements, Opportunities, and Challenges. Journal of Clinical Medicine, 15(21), 8707. https://doi.org/10.3390/jcm15218707
Vancouver
Li X, Zhang L, Zhang L, Xie Y, Xie M, Ji M, et al. Artificial Intelligence in Pulmonary Hypertension: Advancements, Opportunities, and Challenges. Journal of Clinical Medicine. 2026;15(21):8707. doi:10.3390/jcm15218707
BibTeX
@article{Li2026,
author = {Li, Xinyi and Zhang, Linyue and Zhang, Li and Xie, Yuji and Xie, Mingxing and Ji, Mengmeng and He, Qing and Wu, Zhenni and Qin, Shuxuan and Li, Yuman},
title = {Artificial Intelligence in Pulmonary Hypertension: Advancements, Opportunities, and Challenges},
journal = {Journal of Clinical Medicine},
year = {2026},
volume = {15},
number = {21},
pages = {8707},
doi = {10.3390/jcm15218707}
}
EUVIMED